TXNRD2 and prostate carcinoma: Xu and colleagues reported miR-17-3p could repress three major mitochondrial antioxidant enzymes (manganese superoxide dismutase (Mn-SOD), glutathione peroxidase 2 (Gpx2), and thioredoxin reductase 2 (TrxR2)) and enhance the radiosensitivity of prostate cancer cells [38].